Skip to main content
    K

    Kymera Therapeutics Inc (KYMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $121.52
    -4.33 (-3.44%)

    Market Cap: $10.74B

    Last updated: Nov 17, 2026 at 4:35 PM ET

    Kymera Therapeutics Inc (KYMR) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Kymera Therapeutics (KYMR) trades at 119.0x sales and 7.5x book value. Its P/S of 119.0x is above its 5-year median of 34.9x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales119.0x
    Price to book7.5x
    PEGN/A
    FCF yield-2.4%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S119.0x34.9xN/A
    P/B7.5x3.8xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 6 year ends shown, its P/S ranged from 18.9x in 2023 to 160.7x in 2025. 2025 was the highest of those years.

    Year endPriceP/SP/B
    2025$77.81160.7x4.2x
    2024$40.2363.1x3.9x
    2023$25.4618.9x3.8x
    2022$24.9628.9x2.9x
    2021$63.4941.6x7.1x
    2020$62.0054.2x9.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About KYMR

    What is KYMR's price to sales ratio?

    Kymera Therapeutics has a price to sales ratio of 119.0x.